Parker Waichman Files Mounjaro Lawsuit for Texas Resident Alleging Irreversible NAION Vision Loss

Parker Waichman LLP filed a lawsuit on October 29, 2026, on behalf of a Texas resident who developed NAION, an irreversible eye condition, after taking Eli Lilly's Mounjaro, according to a PR Newswire release published November 2, 2026. The case is Swinney v. Eli Lilly and Company, Docket No. 2:26-cv-08305.

The Swinney Case Against Eli Lilly

Parker Waichman LLP - Personal Injury Accident Attorneys is a national law firm that handles defective-drug and personal-injury cases. The firm alleges that Eli Lilly did not adequately warn patients and physicians in the United States about the risk of NAION and permanent vision loss tied to Mounjaro.

Mounjaro, whose active ingredient is tirzepatide, was originally developed to treat Type 2 diabetes. Eli Lilly markets the same active ingredient as Zepbound for weight loss. NAION cuts off blood flow to the optic nerve and causes permanent vision loss.

Regulators outside the United States have acted. Health Canada updated the Product Monograph for Mounjaro to include NAION safety information on June 23, 2026. Australia's Therapeutic Goods Administration announced NAION-related updates to the Product Information for GLP-1 receptor agonists, including Mounjaro, on July 23, 2026, advising that sudden vision loss should prompt urgent ophthalmologic evaluation.

"NAION is a devastating, and permanent, eye injury diagnosis," said Jason S. Goldstein, Senior Litigation Counsel at Parker Waichman and Co-Chair of the Plaintiffs' Executive Committee in the federal GLP-1 NAION multidistrict litigation, MDL 3163. "Patients in the United States deserved that same warning, and Eli Lilly must be held accountable."

Parker Waichman's GLP-1 Litigation Record

According to akta.pro company records, Jason Goldstein was appointed in February 2026 as Co-Chair of the Plaintiffs' Executive Committee and Federal-State Court Liaison in MDL 3163, the GLP-1 NAION litigation, by Judge Karen Marston. The same records show the firm filed GLP-1 NAION lawsuits for plaintiffs in Ohio, Massachusetts, Pennsylvania, Florida, Illinois and Tennessee in February 2026.

Earlier NAION Filings by the Firm

Parker Waichman filed lawsuits in July 2026 on behalf of a Georgia resident and a California resident who developed NAION after taking Ozempic, PR Newswire reported. The firm cited studies linking semaglutide to a four- to sevenfold increased risk of NAION. In September 2026, the firm announced an $8.38 million settlement for a 43-year-old construction worker injured by falling concrete in New York City, PR Newswire reported.

What Comes Next in the Mounjaro Litigation

Parker Waichman said it continues to file additional GLP-1 NAION cases and is accepting cases nationwide for people who suffered vision loss after taking Mounjaro, Zepbound, Ozempic, Wegovy or other GLP-1 medications. The firm offers free case reviews through its website.